Savella

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Savella or milnacipran (generic name) is an antidepressant that is also licensed for use in fibromyalgia. No studies have been carried out on the effectiveness of Savella in ME/CFS patients, although off-label use of psychiatric medications in ME/CFS has generally been ineffective.[1]

Theory[edit | edit source]

Evidence[edit | edit source]

Savella is an FDA-approved drug for fibromyalgia, with improvements in pain, sleep and more limited improvements in fatigue.

No clinical trials have been done for Savella/milnacipran in ME/CFS.

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

Perscription only drug.

Notable studies[edit | edit source]

[2]


  • 2011, Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis[3] - (Full text)
  • 2014, Milnacipran versus other antidepressive agents for depression[4] - (Full text)
  • 2014, Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials[5] - (Full text)
  • 2015, Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program[7] - (Full text)
  • 2016, The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study[8] - (Full text)
  • 2018, Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study[9] - (Full text)
  • 2018, Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia[10] - (Full text)

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. ↑ Kim, Do-Young; Lee, Jin-Seok; Park, Samuel-Young; Kim, Soo-Jin; Son, Chang-Gue (January 6, 2020). "Systematic review of randomized controlled trials for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)". Journal of Translational Medicine. 18 (1): 1–12. doi:10.1186/s12967-019-02196-9. ISSN 1479-5876. PMC 6943902. PMID 31906979.
  2. ↑ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580749/
  3. ↑ https://academic.oup.com/rheumatology/article/50/3/532/1790544
  4. ↑ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164845/
  5. ↑ https://journals.lww.com/jclinrheum/Fulltext/2014/06000/Effects_of_Milnacipran_on_the_Multidimensional.4.aspx
  6. ↑ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481368/
  7. ↑ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480575/
  8. ↑ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702190/
  9. ↑ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089099/
  10. ↑ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846183/

double blinded trial A clinical trial is double blinded if neither the participants nor the researchers know which treatment group they are allocated to until after the results are interpreted. This reduces bias. (Learn more: www.nottingham.ac.uk)

Retrieved from "https://me-pedia.org/w/index.php?title=Savella&oldid=96611"